Long-term oncologic outcomes of stent as a bridge to surgery versus emergency surgery in malignant left side colonic obstructions: a meta-analysis

Marco Ceresoli¹, Niccolò Allievi¹, Federico Coccolini¹, Giulia Montori¹, Paola Fugazzola¹, Michele Pisano¹, Massimo Sartelli², Fausto Catena³, Luca Ansaloni¹

¹General and Emergency Surgery Department, Papa Giovanni XXIII Hospital, Bergamo, Italy; ²General and Emergency Surgery Department, Macerata Hospital, Macerata, Italy; ³Emergency Surgery Department, Parma Hospital, Parma, Italy

Contributions: (I) Conception and design: M Ceresoli, N Allievi, F Coccolini, L Ansaloni; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: M Ceresoli, N Allievi, F Coccolini; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Marco Ceresoli. General and Emergency Surgery, Papa Giovanni XXIII Hospital, Piazza OMS 1, 24127 Bergamo, Italy. Email: marco.ceresoli@libero.it.

Background: The placement of a metallic stent as a bridge to surgery (SBTS) could represents an option for the treatment of left-sided malignant colonic obstruction in centres with adequate skills. Several metaanalyses demonstrated better short-term outcomes after SBTS when compared with emergency surgery (ES); however, some studies reported a higher local recurrence rate. The aim of the present review is to investigate the long-term outcomes of stent bridge to surgery as compared to ES.

Methods: A systematic review was performed to retrieve studies comparing long-term oncologic outcomes of SBTS and ES. Local and overall recurrence rate, overall and disease-free survival were retrieved and results were expressed as risk ratios.

Results: Seventeen studies and a total of 1,333 patients were included in the analysis. No significant differences were reported in recurrence rate [risk ratio (RR) =1.11; 95% confidence interval (95% CI): 0.84– 1.47, P=0.47], 3-year mortality (RR =0.90; 95% CI: 0.73–1.12, P=0.34) and 5-year mortality (RR =1.00; 95% CI: 0.82–1.22, P=0.99). There were no differences among randomized and observational studies.

Conclusions: SBTS has similar long-term oncologic outcomes to ES and in centres with appropriate skill should be considered the best treatment option for left-sided malignant colonic obstructions.

Keywords: Colonic stent; emergency surgery (ES); long-term outcomes; colonic obstruction

Submitted Jun 14, 2017. Accepted for publication Aug 08, 2017. doi: 10.21037/jgo.2017.09.04 View this article at: http://dx.doi.org/10.21037/jgo.2017.09.04

Introduction

Colorectal cancer is the most common cause of large bowel obstruction, which represents the presentation of disease in about 10% of the patients (1). This condition requires an immediate treatment with surgical intervention, with related high morbidity and mortality (2,3). In the 90s the insertion of self-expandable metallic stents (SEMS) has been proposed as an alternative to surgery, both for palliation in advanced disease and as a stent as a bridge to surgery (SBTS) in order to solve the obstruction and to allow delayed elective surgery. Several randomized trials investigated this issue and were summarized in several meta-analyses: SBTS resulted in a lower morbidity, with more favorable short-term results (4-7). The World Society of Emergency Surgery (WSES) Guidelines on left-sided malignant colonic obstruction recommended SBTS as the better option when and where skills are available (8). SBTS developed a good diffusion as a treatment option due to favorable shortterm outcomes; however, the long-term prognosis of this treatment has not been well clarified.

Patients with colorectal obstructing cancer carry a worse prognosis as compared to elective patients without obstructive features (9,10). Moreover, concerns regarding the oncologic outcomes after the insertion of SEMS have been expressed: stenting is suspected to increase local and systemic neoplastic seeding. In particular, the direct effect of mechanical compression of the tumour could induce haematogenous spread and, in case of perforation, the risk of peritoneal involvement would be increased (11-16); however, the real effect on overall survival remains unclear, with contrasting results reported in literature.

The aim of this systematic review and meta-analysis is to investigate the long-term outcomes of SBTS as compared to emergency surgery (ES) in left-sided colorectal obstructing cancers, in order to clarify the real effect on disease free survival and overall survival.

Methods

Literature search and study selection

A systematic review was performed in Medline, Embase, PubMed, Cochrane Central Register of Controlled Trials (CCTR) and Cochrane Database of Systematic Reviews (CDSR) until 20th January 2017. The following terms were used combined with AND/OR: colonic stent, stent bridge to surgery, large bowel malignant obstruction, oncologic outcomes. All the titles and abstracts of retrieved references were reviewed independently by two researchers (M Ceresoli and N Allievi) and those identified as potentially relevant were included in the full-text analysis and then selected if they met the inclusion criteria.

Selection criteria

For the purposes of the current meta-analysis inclusion and exclusion criteria were defined as follows: full-text publications written in English reporting follow-up comparison between colonic SBTS and ES in left-sided and rectum obstructive cancer were selected. Either randomized trial and prospective or retrospective comparative cohort studies were initially selected, in order to maximize the number of patients. Studies were excluded if they regarded right side obstructive cancer or if they included no data about the long-term follow-up. Case series, letters, case reports and review were also excluded.

Data extraction, outcome measures

For each selected paper the following elements were retrieved: study protocol and design, period of study, number of participant centres, number of included patients and data about follow up including median follow-up, 3-year and 5-year mortality and recurrence rate, overall recurrence rate and local recurrence rate. Where available, data of subgroup of patients with potential curative resections were also analyzed. In case data about long-term outcomes were not available as proportion or percentages, we estimated the rate from the Kaplan-Meier survival curves with the highest possible accuracy and then the number of event were calculated.

Assessing risk of bias

For randomized controlled trials the risk of bias was assessed comprehensively according to the guidelines of the Cochrane Collaboration (17), attributing a judgement for the following items: random sequence generation, allocation concealment, blinding of participants, blinding of outcome assessment, assessment of incomplete data outcome, selective reporting and other source of bias. For the prospective and retrospective comparative cohort studies the quality of the included studies and the risk of bias were assessed using the MINORS score (18).

Statistical analysis

Data was analysed with Review Manager (RevMan) (Version 5.3 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). Outcomes were expressed as risk ratio (RR) and 95% confidence interval (95% CI) and were calculated with the fixed-effect and random-effect models of the Mantel-Haenszel test (19,20); statistical heterogeneity was quantified using the I^2 inconsistency test and, when significant (P<0.1), the sole results of the random-effects model were reported.

Results

Selected studies

A total number of 1,083 abstract were retrieved and, after review of title and abstract, 25 were assessed for eligibility; there was good agreement between the two authors. Among them, after full text review, 17 studies were included for the analysis: 5 RCTs (21-25), 3 prospective comparative cohort

studies (16,26,27) and 9 retrospective comparative cohort studies (13-15,28-33). Five studies did not report followup data (34-38), 2 studies reported short-term outcomes of other included trials (39,40) and were also excluded. A retrospective comparative cohort study reported unclear data about long-term follow up, therefore it was decided to exclude it from the analysis (41).

Table 1 shows the characteristics of the included studies. See the PRISMA flow diagram in *Figure 1*.

All the included studies had similar study protocols, with the exception of the study design; all but two (26,32) reported the median follow-up, ranging between 16 and 84 months. Eleven studies reported the oncologic treatment and the pooled rate of patients receiving adjuvant chemotherapy after surgery was similar for both the groups (63% vs. 54%, RR =1.08; 95% CI: 0.95–1.23, P=0.26). *Table 1* shows the characteristics of included studies.

Risk of bias and quality of the studies

All the included RCT were judged as at low risk of bias, according to the Cochrane collaboration tool. Two trials were discontinued prematurely due to the high rate of anastomotic leak within the ES group (22) and to the high comorbidity rate in the stent group (SBTS) (24). Moreover, the trial by Ghazal did not report data as intention-to-treat analysis but as per protocol analysis (23) (*Table 2*).

The quality of comparative cohort studies was assessed using the MINORS score; no study obtained the maximum score (*Table 1*).

Overall and local recurrence

A total of 13 studies reported the recurrence rate and 1089 patients were included in the analysis: there were no significant differences between SBTS and ES (RR =1.11; 95% CI: 0.84–1.47, P=0.47). There were no differences among randomized and observational studies. Ten studies reported the rate of local recurrence and no significant differences were depicted (RR =1.41; 95% CI: 0.89–2.23, P=0.14). There were no differences among RCT and observational studies (*Figure 2*).

3-year mortality

Sixteen studies reported data about 3-year mortality and 1,274 patients were included in the analysis: there were no significant differences among the two groups (RR = 0.90; 95%)

CI: 0.73-1.12, P=0.34) without differences among different study designs. Including only patients who underwent potentially curative resection, no differences were found (RR =1.04; 95% CI: 0.78-1.39, P=0.78) (*Figure 3*).

5-year mortality

A total of 865 patients from eleven studies were included in the analysis for 5-year mortality: extrapolated data showed no significant differences (RR =1.00; 95% CI: 0.82–1.22, P=0.99). Including in the analysis only patients with potentially curative resections, data from 8 studies were available and no significant differences were reported (RR =0.95; 95% CI: 0.53–1.69, P=0.86) (*Figure 4*).

3- and 5-year recurrence

Data regarding recurrence at three years was available from only seven studies: there was no significant difference among the two groups (RR =1.15; 95% CI: 0.95-1.39, P=0.14); data for the five-year outcome was available from six studies and no differences were found with the metaanalysis (RR =1.05; 95% CI: 0.88-1.25, P=0.59).

Discussion

The results of the present meta-analysis show that longterm oncological outcomes of patients treated with SBTS are comparable with those of patients treated with ES in case of left-sided malignant colonic obstruction. In particular, the pooled results of all the included studies did not show any differences in terms of local or systemic recurrence and no differences in 3- and 5-year survival.

The rationale of SEMS positioning as a bridge to surgery is to resolve the acute situation with colonic decompression, therefore transforming ES into scheduled or elective. The clinical success of the SEMS allows stabilization of comorbidities, improvement of nutritional status, accurate staging and definition of a tailored treatment for the patients, in the best conditions available. Patients with obstructing colonic tumour carry a worse prognosis than patients presenting without the obstructive picture (10). The increased interstitial pressure in the neoplastic mass can play a pivotal role in cells dissemination and it has been associated with cell shedding and tumour embolisation into lymphatic vessels (42,43).

The role of SEMS in neoplastic dissemination is an issue of great debate among surgeons, as demonstrated

Study ID	Year of	Country	Study	Includ	Included patients	ents	Centres	Included patients	Ē	Years of	ACT (%)	(%)	Median follow-up	lian v-up	Risk of bias/ MINORS
	publication		design	Total	SBTS	ES		cnaracteristics	anaıysıs	stuay	SBTS	ES	SBTS	ES	score
Arezzo	2016	ltaly, Spain	RCT	115	56	59	2	Only curative resections	×	2008–2015	66	70	16	16	Low
Alcantara	2011	Spain	RCT	28	15	13	-	Only curative resections	×	2004–2006	n/a	n/a	37	37	Medium
Ghazal	2013	Egypt	RCT	60	30	30	.	Only curative resections		2009–2012	100	100	18	18	Low
Sloothaak	2014	Netherlands	RCT	58	26	32	25	Only curative resections	×	2007–2009	50	46	41	45	Low
Tung	2013	Hong Kong, China	RCT	48	24	24	-	All patients	×	2002-2005	54	75	32	65	Low
Dastur	2008	NU	RC	42	19	23	-	All patients	×	1997–2004	n/a	n/a	21	30	18/24
Gianotti	2013	Italy	РС	91*	45*	46*	-	Subgroup analysis of curative resections for cancer		2004–2011	n/a	n/a	n/a	n/a	16/24
Gorissen	2013	N	РС	105	62	43	-	Only curative resections	×	2006–2012	41	25	32	33	17/24
Ю	2016	Hong Kong, China	RC	102	62	40	-	Only curative resections	×	2006–2014	45	27	21	25.5	18/24
Kavanagh	2013	Ireland	RC	49	23	26	-	Only curative resections	×	2005–2011	n/a	n/a	27.4	26	18/24
Kim	2013	South Korea	RC	95	25	70	-	All patients		1996–2007	84	65	43	54	20/24
Kim	2016	South Korea	RC PS matched	168	112	56	Q	Only curative resections	×	2004–2010	83	78	45	49	18/24
Kwak	2016	South Korea	RC PS matched	84	42	42	-	All patients	×	2005–2011	60	73	42.1	52.8	18/24
Quereshy	2014	Hong Kong, China	РС	67	28	39	-	Only curative resections	×	1998–2008	n/a	n/a	26.5	31.3	17/24
Sabbagh	2013	France	RC PS adjusted	87	48	39	0	All patients	×	1998–2011	56	43	30	37	13/24
Saida	2003	Japan	RC	84	44	40	-	All patients		1986–2001	66	53	84	84	14/24
Yan	2017	China	RC	60	27	33	-	All patients	×	2007-2012	70	45	n/a	n/a	17/24




Figure 1 PRISMA flow diagram.

Table 2 Risk of bias assessment of RCT included

Study ID	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias
Alcantara 2011	Unclear	Unclear	Adequate	Adequate	Adequate	Adequate	Premature ending
Arezzo 2016	Adequate	Adequate	Adequate	Adequate	Adequate	Adequate	None
Tung 2016	Adequate	Adequate	Adequate	Adequate	Adequate	Adequate	None
Ghazal 2013	Adequate	Adequate	Adequate	Adequate	Adequate	Adequate	None
Sloothaak 2014	Adequate	Adequate	Adequate	Adequate	Adequate	Adequate	Premature ending

by concerns raising from several published studies. Maruthachalam *et al.* (11) demonstrated that circulating mRNAs of CEA and CK20 were significantly higher after colonic stenting: the authors identified the tumor manipulation during guidewire insertion and the tumor dilatation during stent deployment as possible culprits of this phenomenon. Moreover, the dilatation and the manipulation could induce shedding and dissemination of cancer cells into the peritoneal cavity.

Gorissen *et al.* (16) reported a higher rate of local recurrence in patients treated with SBTS, especially in younger subjects (32% *vs.* 8%); however, at a multivariate analysis stenting was not correlated to this augmented local recurrence and no effect on overall survival was noted. Kim

	EBT	s	ES			Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	MHH, Fixed, 95% Cl	M-H, Fixed, 95% Cl	
2.2.1 RCT								
Alcantara 2011	4	15	1	13	3.7%	3.47 [0.44, 27.24]		
Arezzo 2016	6	54	7	59	23.4%	0.94 [0.34, 2.61]		
Ghazal 2013	1	29	2	30	6.9%	0.52 [0.05, 5.40]		
Sloothaak 2014	5	26	2	32	6.3%	3.08 [0.65, 14.58]		
Subtotal (95% Cl)		124		134	40.2 %	1.43 [0.70, 2.92]		
Total events	16		12					
Heterogeneity: Chi ² = 3	3.02, df= 3	3 (P = 0).39); l² =	1%				
Test for overall effect:	Z = 0.99 (F	P = 0.3	2)					
2.2.2 Non Randomize								
Choi 2014	2	60	6	180	10.5%	1.00 [0.21, 4.82]		
Gorissen 2013	14	60	6	39	25.4%	1.52 [0.64, 3.61]	- +	
Kavanagh 2013	2	22	1	26	32%	2.36 [0.23, 24.35]		
Kim 2013	0	20	1	61	2.6%	0.98 [0.04, 23.25]		
Kim 2016	7	112	2	56	9.3%	1.75 [0.38, 8.15]		
Quereshy 2014	2	28	3	39	8.8%	0.93 [0.17, 5.20]		
Subtotal (95% Cl)		302		401	59.8 %	1.40 [0.77, 2.54]		
Total events	27		19					
Heterogeneity: Chi ² = (0.75, df = (5 (P = 0).98); I²=	0%				
Test for overall effect:	Z=1.10(F	P = 0.2	7)					
Total (95% CI)		426		535	100.0%	1.41 [0.89, 2.23]	•	
Total events	43		31			[eree, may]	-	
Heterogeneity. Chi ² = (A/P = 0		0%			-+ + + +	
Test for overall effect:	•	· ·	~	0.0			0.05 02 1 5	20
Test for subgroup diffe			· · · · ·	(D = 0	06) I2 - 0	94	FavoursEBTS FavoursES	
reacion subgroup une	actives. U	• - UI	50, u i – T	(r - 0.	30), F – U	00		

Figure 2 Forest plot of local recurrences between patients treated with SBTS or ES. SBTS, stent as a bridge to surgery; ES, emergency surgery.

et al. (14) demonstrated a higher rate of perineural invasion at histopathological examination of tumours treated with SBTS compared to those operated in emergency (76% *vs.* 51%): also in this case, no differences in survival rates were detected.

The role of circulating tumour cells still represents an issue of difficult interpretation with not clear results reported in the Literature: a large multicenter study demonstrated the presence of circulating cells in patients with stage III colorectal cancer but no clinical effects on long-term survivals and recurrences was detected (44). Despite the evidence of neoplastic cell spread from the primary site during the stenting procedure, the results of the current meta-analysis demonstrate that no clinical effects could be detected in long-term survival and prognosis and that SBTS did not affect negatively the oncological outcomes.

A hypothesis may be drawn to explain this phenomenon: post-operative complications affects negatively the oncologic outcomes and survivals (45). As previously demonstrated by several meta-analyses, SBTS has better short-term outcomes in term of post-operative morbidity (4-6); this could result in a higher rate of patients receiving full dose adjuvant chemotherapy with the appropriate timing, with better results in term of survival, as evidenced in the literature (46). Although not significantly, patients treated with SBTS had a higher rate of adjuvant chemotherapy, as compared to those treated with ES (63% vs. 54%) in the included studies of the present meta-analysis. Unfortunately, no data regarding the timing of chemotherapy and the adherence to the protocol is available, hindering definitive evidence-based judgement on this hypothesis.

The results of this meta-analyses should be interpreted at the light of a great limitation: none of the included studies was designed for long-term follow up. As a direct consequence, median follow up times were limited and heterogeneous and survival rates were estimated with the Kaplan Meier method rather than observed. Further accurate studies are needed to investigate the long-term outcomes with a proper design and number of included patients.

872

Ctudu or Cubarous	EBT		ES	Total	Mainht	Risk Ratio	Risk Ratio
Study or Subgroup 2.3.1 RCT	Events	Tota	Events	Tota	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Alcantara 2011	6	15	4	13	3.4%	1.30 [0.47, 3.62]	-
Arezzo 2016	19	54	19	59	7.8%	1.09 [0.65, 1.83]	
Sloothaak 2014	10	26	6	32	4.3%	2.05 [0.86, 4.90]	
Tung 2013	8	24	14	24	6.1%	0.57 [0.30, 1.10]	
Subtotal (95% CI)		119		128	21.6%	1.07 [0.64, 1.78]	
Total events	43		43				
Heterogeneity: Tau ² =				= 0.12); I² = 48%		
Test for overall effect	Z = 0.26 (P = 0.8	0)				
2.3.2 Non Randomiz	ed						
Dastur 2008	9	19	12	23	6.6%	0.91 [0.49, 1.68]	
Gianotti 2013	9	45	21	46	6.1%	0.44 [0.23, 0.85]	
Gorissen 2013	19	60	4	39	3.5%	3.09 [1.14, 8.39]	
Ho 2016	23	62	22	40	9.1%	0.67 [0.44, 1.04]	
Kavanagh 2013	8	22	11	26	5.6%	0.86 [0.42, 1.75]	
Kim 2013	5	25	23	70	4.4%	0.61 [0.26, 1.43]	
Kim 2016	21	112	12	56	6.4%	0.88 [0.46, 1.65]	
Kwak 2016	5	42	10	42	3.6%	0.50 [0.19, 1.34]	
Quereshy 2014	12	28	22	39	7.9%	0.76 [0.46, 1.26]	
Sabbagh 2013	27	48	13	39	7.9%	1.69 [1.01, 2.81]	
Saida 2003	23	44	20	40	9.3%	1.05 [0.69, 1.59]	
Yan 2017	12	27	20	33	8.0%	0.73 [0.44, 1.21]	
Subtotal (95% CI)		534		493	78.4%	0.86 [0.67, 1.10]	◆
Total events	173		190				
Heterogeneity: Tau ² =	= 0.09; Chi ²	= 21.5	0, df = 11	(P = 0.	03); $I^2 = 49$	3%	
Test for overall effect:							
Total (95% CI)		653		621	100.0%	0.90 [0.73, 1.12]	•
Total events	216		233				
Heterogeneity: Tau ² =	= 0.08; Chi ²	= 28.0	6, df = 15	(P = 0.	$(02); I^2 = 43$	7% —	
Test for overall effect							0.2 0.5 1 2 5 Favours EBTS Favours ES

Figure 3 Forest plot of 3-year mortality between patients treated with SBTS or ES. SBTS, stent as a bridge to surgery; ES, emergency surgery.

	EBTS		ES			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Tota	Events	Tota	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
2.6.1 RCT							
Alcantara 2011	6	15	4	13	3.2%	1.30 [0.47, 3.62]	
Tung 2013	12	24	18	24	9.7%	0.67 [0.42, 1.06]	
Subtotal (95% CI)		39		37	12.9%	0.80 [0.44, 1.44]	
Total events	18		22				
Heterogeneity: Tau ² = 0				= 0.23); I² = 30%		
Test for overall effect: 2	C = 0.75 (F	P = 0.4	5)				
2.6.2 Non Randomized	1						
Dastur 2008	14	19	14	23	10.6%	1.21 [0.79, 1.85]	
Ho 2016	28	62	26	40	12.4%	0.69 [0.49, 0.99]	
Kim 2013	8	25	27	70	6.5%	0.83 [0.44, 1.58]	
Kim 2016	23	112	12	56	6.8%	0.96 [0.52, 1.78]	
Kwak 2016	12	42	10	42	5.5%	1.20 [0.58, 2.47]	
Quereshy 2014	19	28	26	39	12.9%	1.02 [0.73, 1.43]	
Sabbagh 2013	36	48	15	39	10.5%	1.95 [1.27, 3.00]	
Saida 2003	26	44	22	40	11.9%	1.07 [0.74, 1.56]	
Yan 2017	14	27	21	33	10.1%	0.81 [0.52, 1.27]	
Subtotal (95% CI)		407		382	87.1%	1.04 [0.84, 1.28]	
Total events	180		173				
Heterogeneity: Tau ² = 0	0.05; Chi ² :	= 15.5	3, df = 8 (P = 0.0	5); I ² = 499	%	
Test for overall effect: Z	C = 0.32 (F	9 = 0.79	5)				
Total (95% CI)		446		419	100.0%	1.00 [0.82, 1.22]	•
Total events	198		195				
Heterogeneity: Tau ² = 0).05; Chi ²	= 18.8	3. df = 10	(P = 0.	$(04); I^2 = 47$		
Test for overall effect: Z							0.5 0.7 1 1.5 2
Test for subaroup differ				(P = 0)	$42) I^2 = 09$	x.	Favours EBTS Favours ES

Figure 4 Forest plot of 5-year mortality between patients treated with SBTS or ES. SBTS, stent as a bridge to surgery; ES, emergency surgery.

Ceresoli et al. Oncologic effect of SEMS as bridge to surgery

Conclusions

The results of the present meta-analysis demonstrate that long-term oncologic outcomes are comparable in patients treated with SBTS or ES for left-sided malignant colonic obstructions. At the light of the favorable short-term outcomes and the absence of long-term clinical effects of the procedure, SBTS should be considered as a valid treatment option in centres with adequate technical skills.

Acknowledgements

We would like to give special thanks to Mrs. Franca Boschini, Papa Giovanni XXIII Hospital Library for the bibliographic research.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

- 1. Yeo HL, Lee SW. Colorectal emergencies: review and controversies in the management of large bowel obstruction. J Gastrointest Surg 2013;17:2007-12.
- Tekkis PP, Kinsman R, Thompson MR, et al. The Association of Coloproctology of Great Britain and Ireland study of large bowel obstruction caused by colorectal cancer. Ann Surg 2004;240:76-81.
- 3. Carraro PG, Segala M, Cesana BM, et al. Obstructing colonic cancer: failure and survival patterns over a tenyear follow-up after one-stage curative surgery. Dis Colon Rectum 2001;44:243-50.
- 4. Cirocchi R, Farinella E, Trastulli S, et al. Safety and efficacy of endoscopic colonic stenting as a bridge to surgery in the management of intestinal obstruction due to left colon and rectal cancer: A systematic review and meta-analysis. Surg Oncol 2013;22:14-21.
- Huang X, Lv B, Zhang S, et al. Preoperative Colonic Stents Versus Emergency Surgery for Acute Left-Sided Malignant Colonic Obstruction: A Meta-analysis. J Gastrointest Surg 2014;18:584-91.
- Tan CJ, Dasari BV, Gardiner K. Systematic review and meta-analysis of randomized clinical trials of selfexpanding metallic stents as a bridge to surgery versus emergency surgery for malignant left-sided large bowel obstruction. Br J Surg 2012;99:469-76.

- Allievi N, Ceresoli M, Fugazzola P, et al. Endoscopic Stenting as Bridge to Surgery versus Emergency Resection for Left-Sided Malignant Colorectal Obstruction: An Updated Meta-Analysis. Int J Surg Oncol 2017;2017:2863272.
- Ansaloni L, Andersson RE, Bazzoli F, et al. Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. World J Emerg Surg 2010;5:29.
- Korenaga D, Ueo H, Mochida K, et al. Prognostic factors in japanese patients with colorectal cancer: The significance of large bowel obstruction—univariate and multivariate analyses. J Surg Oncol 1991;47:188-92.
- Runkel NS, Schlag P, Schwarz V, et al. Outcome after emergency surgery for cancer of the large intestine. Br J Surg 1991;78:183-8.
- Maruthachalam K, Lash GE, Shenton BK, et al. Tumour cell dissemination following endoscopic stent insertion. Br J Surg 2007;94:1151-4.
- 12. Suárez J, Jimenez-Pérez J. Long-term outcomes after stenting as a "bridge to surgery" for the management of acute obstruction secondary to colorectal cancer. World J Gastrointest Oncol 2016;8:105-12.
- Kim JS, Hur H, Min BS, et al. Oncologic outcomes of selfexpanding metallic stent insertion as a bridge to surgery in the management of left-sided colon cancer obstruction: Comparison with nonobstructing elective surgery. World J Surg 2009;33:1281-6.
- Kim HJ, Choi GS, Park JS, et al. Higher rate of perineural invasion in stent-laparoscopic approach in comparison to emergent open resection for obstructing left-sided colon cancer. Int J Colorectal Dis 2013;28:407-14.
- 15. Sabbagh C, Browet F, Diouf M, et al. Is stenting as "a bridge to surgery" an oncologically safe strategy for the management of acute, left-sided, malignant, colonic obstruction? A comparative study with a propensity score analysis. Ann Surg 2013;258:107-15.
- Gorissen KJ, Tuynman JB, Fryer E, et al. Local recurrence after stenting for obstructing left-sided colonic cancer. Br J Surg 2013;100:1805-9.
- Higgins JP, Green S. editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011:Table 7.7.
- Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003;73:712-6.

- 19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
- 20. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987;6:341-50.
- Arezzo A, Balague C, Targarona E, et al. Colonic stenting as a bridge to surgery versus emergency surgery for malignant colonic obstruction: results of a multicentre randomised controlled trial (ESCO trial). Surg Endosc 2017;31:3297-305.
- 22. Alcántara M, Serra-Aracil X, Falcó J, et al. Prospective, controlled, randomized study of intraoperative colonic lavage versus stent placement in obstructive left-sided colonic cancer. World J Surg 2011;35:1904-10.
- 23. Ghazal AH, El-Shazly WG, Bessa SS, et al. Colonic Endolumenal Stenting Devices and Elective Surgery Versus Emergency Subtotal/Total Colectomy in the Management of Malignant Obstructed Left Colon Carcinoma. J Gastrointest Surg 2013;17:1123-9.
- 24. Sloothaak DA, Van Den Berg MW, Dijkgraaf MG, et al. Oncological outcome of malignant colonic obstruction in the Dutch Stent-In 2 trial. Br J Surg 2014;101:1751-7.
- 25. Tung KL, Cheung HY, Ng LW, et al. Endo-laparoscopic approach versus conventional open surgery in the treatment of obstructing left-sided colon cancer: longterm follow-up of a randomized trial. Asian J Endosc Surg 2013;6:78-81.
- 26. Gianotti L, Tamini N, Nespoli L, et al. A prospective evaluation of short-term and long-term results from colonic stenting for palliation or as a bridge to elective operation versus immediate surgery for large-bowel obstruction. Surg Endosc 2013;27:832-42.
- Quereshy FA, Poon JT, Law WL. Long-term outcome of stenting as a bridge to surgery for acute leftsided malignant colonic obstruction. Colorectal Dis 2014;16:788-93.
- Dastur JK, Forshaw MJ, Modarai B, et al. Comparison of short-and long-term outcomes following either insertion of self-expanding metallic stents or emergency surgery in malignant large bowel obstruction. Tech Coloproctol 2008;12:51-5.
- Ho KM, Chan KM, Kwok SY, et al. Colonic selfexpanding metal stent (SEMS) as a bridge to surgery in left-sided malignant colonic obstruction: an 8-year review. Surg Endosc 2017;31:2255-62.
- 30. Kavanagh DO, Nolan B, Judge C, et al. A Comparative Study of Short- and Medium-term Outcomes Comparing Emergent Surgery and Stenting as a Bridge to Surgery in Patients With Acute Malignant Colonic Obstruction. Dis

Colon Rectum 2013;56:433-40.

- 31. Kwak MS, Kim WS, Lee JM, et al. Does Stenting as a Bridge to Surgery in Left-Sided Colorectal Cancer Obstruction Really Worsen Oncological Outcomes? Dis Colon Rectum 2016;59:725-32.
- 32. Yan FH, Lou Z, Liu X, et al. Long-Term Oncological Outcomes of Endoscopic Stenting as A Bridge to Surgery Versus Emergency Surgery for Malignant Colorectal Obstruction: A Comparative Study. J Laparoendosc Adv Surg Tech A 2017;27:611-7.
- 33. Saida Y, Sumiyama Y, Nagao J, et al. Long-term prognosis of preoperative "bridge to surgery" expandable metallic stent insertion for obstructive colorectal cancer: comparison with emergency operation. Dis Colon Rectum 2003;46:S44-9.
- van den Berg MW, Sloothaak DA, Dijkgraaf MG, et al. Bridge-to-surgery stent placement versus emergency surgery for acute malignant colonic obstruction. Br J Surg 2014;101:867-73.
- 35. Pirlet IA, Slim K, Kwiatkowski F, et al. Emergency preoperative stenting versus surgery for acute left-sided malignant colonic obstruction: A multicenter randomized controlled trial. Surg Endosc 2011;25:1814-21.
- Consolo P, Giacobbe G, Cintolo M, et al. Colonic acute malignant obstructions : effectiveness of self-expanding metallic stent as bridge to surgery. Turk J Gastroenterol 2017;28:40-5.
- Ho KS, Quah HM, Lim JF, et al. Endoscopic stenting and elective surgery versus emergency surgery for left-sided malignant colonic obstruction: A prospective randomized trial. Int J Colorectal Dis 2012;27:355-62.
- Ng KC, Law W, Lee Y, et al. Self-Expanding Metallic Stent as a Bridge to Surgery Versus Emergency Resection for Obstructing Left-Sided Colorectal Cancer: A Case-Matched Study. J Gastrointest Surg 2006;10:798-803.
- van Hooft JE, Bemelman WA, Oldenburg B, et al. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: A multicentre randomised trial. Lancet Oncol 2011;12:344-52.
- 40. Cheung HY, Chung CC, Tsang WW, et al. Endolaparoscopic approach vs. conventional open surgery in the treatment of obstructing left-sided colon cancer: a randomized controlled trial. Arch Surg 2009;144:1127-32.
- 41. Choi JM, Lee C, Han YM, et al. Long-term oncologic outcomes of endoscopic stenting as a bridge to surgery for malignant colonic obstruction: Comparison with emergency surgery. Surg Endosc 2014;28:2649-55.
- 42. Lemoine L, Sugarbaker P, Van der Speeten K.

Ceresoli et al. Oncologic effect of SEMS as bridge to surgery

Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol 2016;22:7692.

- 43. Hayashi K, Jiang P, Yamauchi K, et al. Real-time Imaging of Tumor-Cell Shedding and Trafficking in Lymphatic Channels. Cancer Res 2007;67:8223-8.
- Sotelo MJ, Sastre J, Maestro ML, et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol 2015;26:535-41.

Cite this article as: Ceresoli M, Allievi N, Coccolini F, Montori G, Fugazzola P, Pisano M, Sartelli M, Catena F, Ansaloni L. Long-term oncologic outcomes of stent as a bridge to surgery versus emergency surgery in malignant left side colonic obstructions: a meta-analysis. J Gastrointest Oncol 2017;8(5):867-876. doi: 10.21037/jg0.2017.09.04

- 45. Artinyan A, Orcutt ST, Anaya DA, et al. Infectious Postoperative Complications Decrease Long-term Survival in Patients Undergoing Curative Surgery for Colorectal Cancer: A Study of 12,075 Patients. Ann Surg 2015;261:497-505.
- 46. Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and metaanalysis. JAMA 2011;305:2335-42.

876